CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions.
OBJECTIVE
The purpose of this study was to test the hypothesis that CEACAM6 expression is an indicator of adverse pathologic features and clinical outcome in pancreatic adenocarcinoma.


BACKGROUND
Previously, we have demonstrated carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) to be an oncoprotein that plays an important role in the biology of pancreatic adenocarcinoma. Suppression of CEACAM6 expression reduces tumorigenesis and metastasis in vivo.


METHODS
A tissue microarray was constructed using tumor specimens obtained from 89 consecutive patients who had undergone pancreatic resection for pancreatic adenocarcinoma with curative intent. A second microarray containing 54 pancreatic intraepithelial neoplasia (PanIN) lesions was constructed using tissues from a separate cohort of 44 patients. Both arrays were immunostained using a specific anti-CEACAM6 monoclonal antibody. Tumoral CEACAM6 expression was dichotomized into negative and positive immunoreactivity groups. The log-rank test was used to evaluate univariate associations of CEACAM6 expression with prognosis. Survival curves were derived using the Kaplan-Meier method.


RESULTS
Tumoral CEACAM6 expression was detected in 82 (92%) pancreatic adenocarcinoma specimens. CEACAM6 expression was more prevalent in high-grade than in low-grade PanIN lesions (P = 0.0002). Negative tumoral CEACAM6 expression was associated with absence of lymph node metastases (P = 0.012), lower disease stage (P = 0.008), and longer postoperative survival (P = 0.047).


CONCLUSIONS
CEACAM6 is a novel biomarker for pancreatic adenocarcinoma. CEACAM6 warrants further evaluation as both a prognostic factor and a therapeutic target in pancreatic cancer.
Duxbury
Mark S
MS
Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Matros
Evan
E
Clancy
Thomas
T
Bailey
Gerald
G
Doff
Michael
M
Zinner
Michael J
MJ
Ashley
Stanley W
SW
Maitra
Anirban
A
Redston
Mark
M
Whang
Edward E
EE
D000230:Adenocarcinoma / Q000737:chemistry / Q000175:diagnosis* / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD; D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002278:Carcinoma in Situ / Q000175:diagnosis*; D015815:Cell Adhesion Molecules / Q000032:analysis*; D005260:Female; D058851:GPI-Linked Proteins; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000737:chemistry / Q000175:diagnosis* / Q000401:mortality; D011379:Prognosis; D016019:Survival Analysis; D015996:Survival Rate
D015703:Antigens, CD; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C504117:CEACAM6 protein, human; D015815:Cell Adhesion Molecules; D058851:GPI-Linked Proteins
Oral Oncol. 2003 Oct;39(7):648-55
12907203
Mod Pathol. 2003 Sep;16(9):902-12
13679454
J Clin Oncol. 2003 Oct 1;21(19):3638-46
14512395
Oncogene. 2004 Jan 15;23(2):465-73
14724575
Cancer Control. 2004 Jan-Feb;11(1):23-31
14749620
Br J Haematol. 1993 Jan;83(1):30-8
8435334
Br J Cancer. 1993 Jul;68(1):130-6
8318403
J Cell Biol. 1994 Feb;124(4):619-26
8106557
Exp Hematol. 1995 Dec;23(14):1484-91
8542935
Cell Growth Differ. 1996 May;7(5):655-62
8732675
J Clin Oncol. 1997 Jun;15(6):2403-13
9196156
Oncogene. 1998 May;16(20):2681-6
9632144
J Mammary Gland Biol Neoplasia. 1999 Apr;4(2):183-91
10426397
Am J Pathol. 2000 Feb;156(2):595-605
10666389
Pathol Int. 2000 Apr;50(4):273-9
10849312
Cancer Res. 2000 Jul 1;60(13):3419-24
10910050
Cancer Res. 2001 Feb 15;61(4):1707-16
11245487
Clin Cancer Res. 2001 Jul;7(7):1987-91
11448915
Cancer Res. 2002 Feb 1;62(3):819-26
11830538
Neoplasia. 2002 Mar-Apr;4(2):151-63
11896570
Acta Cient Venez. 2001;52(4):304-12
11915449
Oncogene. 2002 Apr 4;21(15):2365-75
11948420
CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26
12568441